1st Circ. Finds No Fraud In Ocular Therapeutix Stock Suit
Law360 (April 9, 2020, 4:33 PM EDT) -- Biotech company Ocular Therapeutix didn't intentionally mislead investors in conference calls and filings about manufacturing problems that led to the U.S. Food and Drug Administration twice denying its steroid treatment for eye pain, the First Circuit said Thursday.
The appeals court, in an opinion by Senior Circuit Judge Norman H. Stahl, affirmed the May 2019 decision by a federal judge in Boston to toss the stock-drop suit on the grounds that investors failed to demonstrate the company knowingly made false statements.
The investors accused Ocular of downplaying negative FDA inspections of its manufacturing facilities. The company also allegedly failed to disclose...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!